Guided Therapeutics (GTHP)

We are a medical technology company focused on developing innovative medical devices that have the potential to improve healthcare. Our primary focus is the sales and marketing of our LuViva® Advanced Cervical Scan non-invasive cervical cancer detection device. The underlying technology of LuViva primarily relates to the use of biophotonics for the non-invasive detection of cancers. LuViva is designed to identify cervical cancers and precancers painlessly, non-invasively and at the point of care by scanning the cervix with light, then analyzing the reflected and fluorescent light.

Company profile

Ticker

GTHP

Exchange

NASDAQ

Website

www.guidedinc.com/

CEO

Mark Faupel

Incorporated

Delaware

Location

Georgia

Fiscal year end

Dec 31

Sector

Manufacturing > Surgical and Medical Instrument Manufacturing

Industry (SIC)

Electromedical & Electrotherapeutic Apparatus

Medtronic • Varian Medical Systems • Conmed • Masimo • Natus Medical • LivaNova • Outset Medical • Fonar • Cutera • Inmode ...

Former names

SPECTRX INC

SEC CIK

0000924515

Corporate docs

Articles of Incorporation & Bylaws

Underwriting Agreements

Plans of Reorganization

Indentures

Material Contracts & Credit Agreements

Subsidiaries Lists

IRS number

582029543

GTHP stock data

1M 1Y 5Y

Press releases

From Benzinga Pro

Olive Resource Capital Completes Acquisition of C$2.5M Portfolio of Assets

2 Aug 22

Toronto, Ontario--(Newsfile Corp. - August 2, 2022) - Olive Resource Capital Inc. (TSXV:OC) ("Olive" or the "Company") is pleased to announce that it has closed the previously announced asset purchase agreement (the

Olive Resource Capital Announces Agreement to Acquire C$2.5M Portfolio of Assets

18 May 22

Toronto, Ontario--(Newsfile Corp. - May 18, 2022) - Olive Resource Capital Inc.

Investment data

Data from SEC filings

Securities sold

Number of investors

Calendar

16 May 22

12 Aug 22

31 Dec 22

Financial summary

Financial statements Chart GTHP financial data

Quarter (USD)	Mar 22	Dec 21	Sep 21	Jun 21
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Annual (USD)	Dec 21	Dec 20	Dec 19	Dec 18
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Cash burn rate (est.)	Burn method: Change in cash		Burn method: Operating income		Burn method: FCF (opex + capex)
	Last Q	Avg 4Q	Last Q	Avg 4Q	Last Q	Avg 4Q
Cash on hand (at last report)	725K	725K	725K	725K	725K	725K
Cash burn (monthly)	(no burn)	43.5K	147.67K	160.5K	59.67K	120.92K
Cash used (since last report)	n/a	191.6K	650.4K	706.92K	262.8K	532.58K
Cash remaining	n/a	533.4K	74.6K	18.08K	462.2K	192.42K
Runway (months of cash)	n/a	12.3	0.5	0.1	7.7	1.6

Beta Read what these cash burn values mean

Financial data from company earnings reports.

Institutional ownership, Q1 2022

GTHP institutional ownership history Ownership history

13F holders	Current	Prev Q	Change
Total holders	0	0
Opened positions	0	0
Closed positions	0	0
Increased positions	0	0
Reduced positions	0	0

13F shares	Current	Prev Q	Change
Total value	0	0
Total shares	0	0
Total puts	0	0
Total calls	0	0
Total put/call ratio	–	–	–

Largest owners	Shares	Value	Change

Largest transactions	Shares	Bought/sold	Change

Data from 13F filings, for the last complete 13F reporting period. For most recent data, click the ownership history button. Values as filed, not updated for current price. Long positions only.

Financial report summary

Competition

Hologic • Qiagen • GSK • Femasys

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability	H.S. sophomore Avg

New words: bore, conflict, deadline, earlier, FINRA, imposed, installment, lock, NMPA, Notification, ongoing, prefunded, Russia, shortly, shown, threshold, tracking, Ukraine, underwritten, unregistered

Removed: aggregated, amending, appealing, ASU, bearing, bifurcate, bifurcation, called, clarifying, Clavijo, commitment, component, COO, depreciated, disposed, earliest, earn, elimination, EPS, exchangeable, expensing, explained, FASB, Finally, forbearance, GPB, Hedging, henceforth, listed, managing, member, modified, nondetachable, noted, notified, occurrence, offsetting, placement, planning, processing, qualify, ratio, reimburse, remain, removing, restructure, retrospective, Rosenstock, rule, scope, separate, separation, Similarly, simple, simplify, standard, subsequently, Topic, treatment, twelve

From filing 10-Q 2022 Q1

Financial reports

View all